Altaris has announced it will acquire the Life Sciences & Healthcare business (LS&H) from Clarivate (NYSE: CLVT) for $600 million.
LS&H is comprised of the Cortellis and Decision Resources Group portfolios. LS&H is an AI-enabled data intelligence products and services business supporting R&D and commercialization decisions for pharmaceutical, biotechnology and medical technology companies.
Altaris, founded in 2002 and based in New York, seeks control and minority equity investments exclusively in healthcare. The firm targets companies within the life sciences/pharmaceutical, provider services and non-reimbursement healthcare industries. Altaris is flexible in its investment sizes.
Following completion of the transaction, which is expected to close in the second half of 2026, LS&H will operate as an independent company.